Press Release: ReNetx : ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium

NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been invited to present as part of a "Clinical Trials 360" symposium at the upcoming American Spinal Cord Injury Association (ASIA) meeting. The NoGo Trap blocks inhibitors in the central nervous system thereby allowing the body to repair itself by re-growing nerve fiber connections. The company was invited "based on the promise and uniqueness of our treatment for spinal cord injury," says ReNetX President and CSO George Maynard. Unlike many other treatments attempting to address acute injury, the NoGo Trap trial will focus on chronic patients who have an injury beyond one year. The breakthrough technology developed in Dr. Stephen Strittmatter's laboratory at Yale has an entirely new approach that has shown successful restoration of neurons in animal studies many months after spinal cord injury.